Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KMT2A oncoproteins induce epigenetic resistance to targeted therapies.
Janssens DH, Duran M, Otto DJ, Wu W, Xu Y, Kirkey D, Mullighan CG, Yi JS, Meshinchi S, Sarthy JF, Ahmad K, Henikoff S. Janssens DH, et al. Among authors: meshinchi s. bioRxiv [Preprint]. 2024 Aug 12:2023.12.29.573681. doi: 10.1101/2023.12.29.573681. bioRxiv. 2024. PMID: 38234854 Free PMC article. Preprint.
EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion.
Buteyn NJ, Burke CG, Sartori VJ, Deering-Gardner E, DeBruine ZJ, Kamarudin D, Chandler DP, Monovich AC, Perez MW, Yi JS, Ries RE, Alonzo TA, Ryan RJ, Meshinchi S, Triche TJ Jr. Buteyn NJ, et al. Among authors: meshinchi s. bioRxiv [Preprint]. 2024 Jun 25:2024.05.14.594150. doi: 10.1101/2024.05.14.594150. bioRxiv. 2024. PMID: 38798454 Free PMC article. Preprint.
MLL oncoprotein levels influence leukemia lineage identities.
Janssens DH, Duran M, Otto DJ, Wu W, Xu Y, Kirkey D, Mullighan CG, Yi JS, Meshinchi S, Sarthy JF, Ahmad K, Henikoff S. Janssens DH, et al. Among authors: meshinchi s. Nat Commun. 2024 Oct 29;15(1):9341. doi: 10.1038/s41467-024-53399-8. Nat Commun. 2024. PMID: 39472576 Free PMC article.
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang TT, Loken MR, Brodersen LE, Loeb KR, Scheinberg DA, Le Q, Meshinchi S. Kirkey DC, et al. Among authors: meshinchi s. Blood Adv. 2023 Apr 11;7(7):1178-1189. doi: 10.1182/bloodadvances.2022008304. Blood Adv. 2023. PMID: 35984639 Free PMC article.
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.
Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, Loken MR, Brodersen L, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. Le Q, et al. Among authors: meshinchi s. J Clin Invest. 2022 Nov 15;132(22):e157101. doi: 10.1172/JCI157101. J Clin Invest. 2022. PMID: 36136600 Free PMC article.
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate.
Tang T, Le Q, Castro S, Pardo L, McKay CN, Perkins L, Smith J, Kirkey D, Abrahams C, Bedard K, Molina A, Brodersen LE, Loken MR, Tarlock K, Meshinchi S, Loeb KR. Tang T, et al. Among authors: meshinchi s. Blood Adv. 2022 Nov 22;6(22):5933-5937. doi: 10.1182/bloodadvances.2022008503. Blood Adv. 2022. PMID: 36149945 Free PMC article. No abstract available.
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia.
Le Q, Tang T, Leonti A, Castro S, McKay CN, Perkins L, Pardo L, Kirkey D, Hylkema T, Call L, Manselle M, Abrahams C, Bedard K, Molina A, Brodersen LE, Loken MR, Tarlock K, Meshinchi S, Loeb KR. Le Q, et al. Among authors: meshinchi s. Blood Adv. 2023 May 9;7(9):1666-1670. doi: 10.1182/bloodadvances.2022008303. Blood Adv. 2023. PMID: 36595452 Free PMC article. No abstract available.
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Tarlock K, Gerbing RB, Ries RE, Smith JL, Leonti A, Huang BJ, Kirkey D, Robinson L, Peplinski JH, Lange B, Cooper TM, Gamis AS, Kolb EA, Aplenc R, Pollard JA, Alonzo TA, Meshinchi S. Tarlock K, et al. Among authors: meshinchi s. Blood Adv. 2024 May 14;8(9):2094-2103. doi: 10.1182/bloodadvances.2023011980. Blood Adv. 2024. PMID: 38295280 Free PMC article.
259 results